Bay Area Reporter - July 20, 2006
Bob Roehr

"This is a landmark for those suffering with HIV and AIDS," said acting FDA Commissioner Andrew von Eschenbach at a highly unusual news conference announcing the approval. "Compliance with therapy is as important as the therapy itself for a successful outcome."

The revolution in treating HIV that began in 1996 with the introduction of highly active antiretroviral therapy initially came with a high burden of taking multiple pills and often accompanied with food restrictions that strung out the dosing over many hours. Both made compliance more difficult. And HIV is a virus that will readily mutate resistance if that regimen is not rigorously maintained.

Second generation drugs eased those restrictions and made triple drug combinations easier to take, reducing a regimen to two pills once or twice a day. So in that sense, Atripla represents more of a symbolic culmination of the process rather than a significant change in the lives of people living with HIV.

It also represents an unprecedented collaboration between two companies, Gilead Sciences, which developed Viread and Emtriva, and Bristol-Myers Squibb, which makes Sustiva. They had to overcome many technical issues in order to formulate the three drugs into the same pill.

The companies have set a wholesale price of $1,150.88 for a 30-day supply. That is the same as they currently charge for the individual components. New drugs and combinations traditionally have been priced higher.

AIDS advocates were pleased with the companies' holding the line on pricing. "Atripla pricing appears to be in line with what advocates fought for," said Bill Arnold, head of Title II Community AIDS National Network, the advocacy group that focuses on the AIDS Drug Assistance Program portion of the federal response to HIV.

The most significant impact of this may be on the wallets of people taking the drug. Many health insurance plans require that a patient make a co-payment, often $25, for each month's supply of a drug. A regimen of three separate drugs would mean co-payments of $75 a month. A single pill regimen would reduce that out of pocket cost by as much as $600 a year, a significant savings for those with a low income.

The pill will be salmon colored for sale in the U.S. and the industrialized world, and white for sale in developing countries. Companies often create slightly different versions of a pill when they set different prices for those markets, so as to reduce the risk of diversion from the cheaper to the more expensive market.

This suggests that the companies will steeply discount Atripla for sales where the pandemic is most extensive, as has become common with other HIV drugs. However, those matters are clouded by patent and drug approval issues in some developing countries that first must be resolved.

060720
BR060707

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .